Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Jw Cayman Therapeutics Co Ltd

2126
Current price
1.4 HKD +0.03 HKD (+2.19%)
Last closed 1.42 HKD
ISIN KYG5210T1040
Sector Healthcare
Industry Biotechnology
Exchange Hong Kong Stock Exchange
Capitalization 602 429 631 HKD
Yield for 12 month -45.31 %
1Y
3Y
5Y
10Y
15Y
2126
21.11.2021 - 28.11.2021

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in the People's Republic of China. It offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China. Address: Building B, Shanghai, China

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

18.68 HKD

P/E ratio

Dividend Yield

Current Year

+174 024 259 HKD

Last Year

+145 843 007 HKD

Current Quarter

+87 824 917 HKD

Last Quarter

Current Year

+88 304 374 HKD

Last Year

+58 812 860 HKD

Current Quarter

+44 856 366 HKD

Last Quarter

Key Figures 2126

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -427 810 618 HKD
Operating Margin TTM -277.04 %
PE Ratio
Return On Assets TTM -13.55 %
PEG Ratio
Return On Equity TTM -34.67 %
Wall Street Target Price 18.68 HKD
Revenue TTM 173 098 368 HKD
Book Value 3.67 HKD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -1.1 %
Dividend Yield
Gross Profit TTM 58 812 863 HKD
Earnings per share
Diluted Eps TTM
Most Recent Quarter II 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics 2126

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History 2126

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation 2126

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.4324
Price Sales TTM 3.4803
Enterprise Value EBITDA 0.1195
Price Book MRQ 0.3801

Financials 2126

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 2126

For 52 weeks

1.19 HKD 3.49 HKD
50 Day MA 1.52 HKD
Shares Short Prior Month
200 Day MA 1.81 HKD
Short Ratio
Shares Short
Short Percent